Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial.
OBJECTIVE
To evaluate the effect of adjunctive intraocular triamcinolone acetonide (TA) in silicone-filled eyes on outcomes of vitreoretinal surgery for proliferative vitreoretinopathy (PVR).


METHODS
Prospective, randomized, controlled clinical trial.


METHODS
Seventy-five eyes with rhegmatogenous retinal detachment and PVR grade C (posterior, anterior, or both) undergoing vitrectomy combined with silicone oil tamponade were included. Of these, 38 eyes were assigned randomly to the adjunctive treatment, whereas 37 eyes served as controls.


METHODS
All eyes underwent pars plana vitrectomy, membrane peeling, and silicone oil exchange, with or without relaxing retinotomy or retinectomy. In the treatment group, 4 mg TA was injected into the silicone-filled vitreous cavity at the end of the procedure. Silicone oil was removed 3 months after surgery in eyes with attached retinas.


METHODS
The primary outcome measure was retinal reattachment rate at 6 months. Secondary outcome measures included visual acuity, rate of recurrent PVR, reoperation rate, and rise of intraocular pressure.


RESULTS
Retinal reattachment without any reoperation was achieved in 32 eyes (84.2%) and 29 eyes (78.4%) in the adjunctive treatment and control groups, respectively, at 6 months (P = 0.5). No statistically significant difference was observed between the 2 groups in terms of any of the secondary outcome measures (P>0.05).


CONCLUSIONS
The outcomes of vitreoretinal surgery for established PVR are not improved significantly by adjunctive TA injection in silicone-filled eyes.
Ahmadieh
Hamid
H
Ophthalmic Research Center, Labbafinejad Medical Center, Shahid Beheshti University, M.C., Tehran, Iran.
Feghhi
Mostafa
M
Tabatabaei
Homa
H
Shoeibi
Nasser
N
Ramezani
Alireza
A
Mohebbi
Mohammad Reza
MR
D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007267:Injections; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012163:Retinal Detachment / Q000601:surgery*; D012827:Silicone Oils / Q000008:administration & dosage*; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014821:Vitrectomy; D018630:Vitreoretinopathy, Proliferative / Q000188:drug therapy* / Q000601:surgery*; D014822:Vitreous Body
D007166:Immunosuppressive Agents; D012827:Silicone Oils; D014222:Triamcinolone Acetonide